Overview

Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb

Status:
Active, not recruiting

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

The Phase II study proposed here assesses the hypothesis that replacing doxorubicin by Myocet® in the R-CHOP regimen would yield comparable antitumour efficacy with a lower cardiotoxicity for first-line treatment in elderly patients with non-localised DLBCL/Follicular lymphoma grade IIIb

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Treatments:

Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Prednisone
Rituximab
Vincristine